Hence, nobiletin is proposed to be a good candidate drug for natural compound-based therapeutics in cancer immunotherapy against NSCLC cells and in order to confirm this, in vivo experimentation needed for further analysis that could confirm that nobiletin inhibits PD-L1 expression through mir-197 regulation instead of miR-34a. Here, CD274 is linked to non-small cell lung carcinoma.